Hereditary forms of primary hyperparathyroidism

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access



Primary hyperparathyroidism is a common disorder of mineral homeostasis, characterized by overproduction of parathyroid hormone and upper normal or elevated calcium levels due to hyperplasia or a tumor of parathyroid gland. 90-95% of cases of primary hyperparathyroidism are sporadic, while hereditary genetic forms occur in 5–10 % of all cases.

Primary hyperparathyroidism as the component of hereditary syndromes can present in various clinical forms (asymptomatic, symptomatic), can be associated with other endocrine or non-endocrine diseases, and require special approaches to treatment. Given that primary hyperparathyroidism is one of the most common components of these syndromes, it can be used as an important diagnostic tool in identifying affected families. This review is devoted to modern ideas about the clinical course and genetic characteristics of hereditary variants of primary hyperparathyroidism and the diagnostic and treatment algorithms recommended today.

The review considers primary hyperparathyroidism as a component of hereditary syndromes including multiple endocrine neoplasias types 1, 2A and 4 and syndrome of hyperparathyroidism with a jaw tumor. Also non-syndromic hereditary forms are descripted, such as familial isolated hyperparathyroidism, familial hypocalciuric hypercalcemia, and severe neonatal primary hyperparathyroidism.

About the authors

Anna Gorbacheva

Endocrinology Research Centre, Moscow, Russian Federation

Author for correspondence.
ORCID iD: 0000-0003-2669-9457
SPIN-code: 9815-7509
Scopus Author ID: 57190977461
ResearcherId: F-2798-2018

Russian Federation, 11 Dm.Ulyanova street, 117036 Moscow, Russia

Anna Eremkina

Endocrinology Research Centre, Moscow, Russian Federation

ORCID iD: 0000-0001-6667-062X
SPIN-code: 8848-2660

Russian Federation, 11 Dm.Ulyanova street, 117036 Moscow, Russia

Natalya Mokrysheva

Endocrinology Research Centre, Moscow, Russian Federation

ORCID iD: 0000-0002-9717-9742
SPIN-code: 5624-3875

Russian Federation, 11 Dm.Ulyanova street, 117036 Moscow, Russia


  • Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011;365(25):2389–97. doi: 10.1056/NEJMcp1106636.
  • Cetani F, Saponaro F, Borsari S, Marcocci C. Familial and Hereditary Forms of Primary Hyperparathyroidism. Front Horm Res. 2019;51:40–51. doi: 10.1159/000491037.
  • Thakker R V. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1–2):2–15. doi: 10.1016/j.mce.2013.08.002.
  • Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck’s Arch Surg. 2015;400(8):867–86. doi: 10.1007/s00423-015-1342-7.
  • Huang J, Gurung B, Wan B et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature. 2012;482(7386):542–6. doi: 10.1038/nature10806.
  • Wu T, Hua X. Menin represses tumorigenesis via repressing cell proliferation. Am J Cancer Res. 2011;1(6):726–39.
  • Giusti F, Cianferotti L, Boaretto F et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349–59. doi: 10.1007/s12020-017-1234-4.
  • Pardi E, Borsari S, Saponaro F et al. Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS One. 2017;12(10):e0186485. doi: 10.1371/journal.pone.0186485.
  • Thevenon J, Bourredjem A, Faivre L et al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d’etude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet. 2013;22(10):1940–8. doi: 10.1093/hmg/ddt039.
  • Bartsch DK, Slater EP, Albers M et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab. 2014;99(11):E2387-91. doi: 10.1210/jc.2013-4432.
  • Wu Y, Gao L, Guo X et al. Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China. Pituitary. 2019;22(2):113–23. doi: 10.1007/s11102-019-00939-x.
  • Verges B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87(2):457–65. doi: 10.1210/jcem.87.2.8145.
  • Jensen RT, Norton JA. Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. Pancreas. 2017;46(5):589–94. doi: 10.1097/MPA.0000000000000825.
  • Eller-Vainicher C, Chiodini I, Battista C et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24(8):1404–10. doi: 10.1359/jbmr.090304.
  • Schaaf L, Pickel J, Zinner K et al. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes. 2007;115(8):509–17. doi: 10.1055/s-2007-970160.
  • Goudet P, Dalac A, Le Bras M et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’etude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568–77. doi: 10.1210/jc.2014-3659.
  • Мамедова Е.О., Мокрышева Н.Г., Пигарова Е.А. и соавт. Молекулярно-генетические особенности первичного гиперпаратиреоза у пациентов молодого возраста // Проблемы эндокринологии. — 2016. — №2. — С.4–11. [Mamedova E.O., Mokrysheva N.G., Pigarova E.A. et al. Molecular and genetic features of primary hyperparathyroidism in young patients. Problemy endocrinologii. 2016;2:4-11. (In Russ).] doi: 10.14341/probl20166224-11.
  • Ростомян Л.Г. Синдром множественных эндокринных неоплазий 1 типа: распространенность среди пациентов с первичным гиперпаратиреозом, клинические и молекулярно-генетические характеристики: Дис. … канд. мед.наук. - Москва; 2011. [ Rostomyan LG. Sindrom mnozhestvennyh endokrinnyh neoplasii 1 tipa: rasprostranennost sredi patsientov s pervichnim gyperparatyreozom, klinicheskiye i molekulyarno-geneticheskiye kharakteristiky. [dissertation] Moscow; 2011. (In Russ). ]
  • Keutgen XM, Nilubol N, Agarwal S et al. Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. Ann Surg Oncol. 2016;23(Suppl 5):701–7. doi: 10.1245/s10434-016-5467-x.
  • Skandarajah A, Barlier A, Morlet-Barlat N et al. Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg. 2010;34(6):1294–8. doi: 10.1007/s00268-009-0388-5.
  • Starker LF, Akerstrom T, Long WD et al. Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012;3(1–2):44–51. doi: 10.1007/s12672-011-0100-8.
  • Roijers JF, de Wit MJ, van der Luijt RB et al. Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. Eur J Clin Invest. 2000;30(6):487–92.
  • Cardinal JW, Bergman L, Hayward N et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet. 2005;42(1):69–74. doi: 10.1136/jmg.2003.017319.
  • Lairmore TC, Piersall LD, DeBenedetti MK et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg. 2004;239(5):637. doi: 10.1097/01.sla.0000124383.98416.8d.
  • Goudet P, Murat A, Binquet C et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249–55. doi: 10.1007/s00268-009-0290-1.
  • Thakker RV, Newey PJ, Walls GV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. doi: 10.1210/jc.2012-1230.
  • Twigt BA, Scholten A, Valk GD et al. Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis. 2013;8:50. doi: 10.1186/1750-1172-8-50.
  • Pieterman CRC, van Hulsteijn LT, den Heijer M et al. Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Ann Surg. 2012;255(6):1171–8. doi: 10.1097/SLA.0b013e31824c5145.
  • Lairmore TC, Govednik CM, Quinn CE et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2014;156(6):1325–6. doi: 10.1016/j.surg.2014.08.006.
  • Elaraj DM, Skarulis MC, Libutti SK et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003;134(6):855–8. doi: 10.1016/S0039.
  • Schreinemakers JMJ, Pieterman CRC, Scholten A et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg. 2011;35(9):1993–2005. doi: 10.1007/s00268-011-1068-9.
  • Lambert LA, Shapiro SE, Lee JE et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005;140(4):374–82. doi: 10.1001/archsurg.140.4.374.
  • Salmeron MDB, Gonzalez JMR, Sancho Insenser J et al. Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World J Surg. 2010;34(6):1325–31. doi: 10.1007/s00268-010-0605-2.
  • Goudet P, Cougard P, Verges B et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D’etude des Neoplasies Endocriniennes Multiples Study Group. World J Surg. 2001;25(7):886–90.
  • Salmeron MDB, Gonzalez JMR, Rios A et al. Primary hyperparathyroidism associated with MEN 1: Experience in 71 cases. Cir Esp. 2018;96(10):627–33. doi: 10.1016/j.ciresp.2018.06.014.
  • Powell AC, Alexander HR, Pingpank JF et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008;144(6):874–8. doi: 10.1016/j.surg.2008.08.031.
  • Versnick M, Popadich A, Sidhu S et al. Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism. Surgery. 2013;154(1):101–5. doi: 10.1016/j.surg.2013.03.004.
  • Saponaro F, Faggiano A, Grimaldi F et al. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin Endocrinol (Oxf). 2013;79(1):20–6. doi: 10.1111/cen.12108.
  • Giusti F, Cianferotti L, Gronchi G et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine. 2016;52(3):495–506. doi: 10.1007/s12020-015-0696-5.
  • Romei C, Pardi E, Cetani F, Elisei R. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol. 2012;2012:705036. doi: 10.1155/2012/705036.
  • Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71. doi: 10.1210/jcem.86.12.8070.
  • Giusti F, Cavalli L, Cavalli T, Brandi ML. Hereditary hyperparathyroidism syndromes. J Clin Densitom. 2013;16(1):69–74. doi: 10.1016/j.jocd.2012.11.003.
  • Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192–202. doi: 10.1038/nrendo.2016.11.
  • Wells SAJ, Asa SL, Dralle H et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567–610. doi: 10.1542/peds.2018-3062.
  • Haddad RI, Nasr C, Bischoff L et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018;16(12):1429–40. doi: 10.6004/jnccn.2018.0089.
  • Tonelli F, Marcucci T, Giudici F et al. Surgical approach in hereditary hyperparathyroidism. Endocr J. 2009;56(7):827–41.
  • Moley JF, Skinner M, Gillanders WE et al. Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2. Ann Surg. 2015;262(4):641–6. doi: 10.1097/SLA.0000000000001464.
  • Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(42):15558–63. doi: 10.1073/pnas.0603877103.
  • Alevizaki M, Stratakis CA. Multiple endocrine neoplasias: advances and challenges for the future. J Intern Med. 2009;266(1):1–4. doi: 10.1111/j.1365-2796.2009.02108.x.
  • Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94(5):1826–34. doi: 10.1210/jc.2008-2083.
  • Georgitsi M, Raitila A, Karhu A et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321–5. doi: 10.1210/jc.2006-2843.
  • Molatore S, Marinoni I, Lee M et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat. 2010;31(11):E1825-35. doi: 10.1002/humu.21354.
  • de Laat JM, van der Luijt RB, Pieterman CRC et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14(1):182. doi: 10.1186/s12916-016-0708-1.
  • Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013;41:63–78. doi: 10.1159/000345670.
  • Crona J, Gustavsson T, Norlen O et al. Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2015;22 Suppl 3:S1428-35. doi: 10.1245/s10434-014-4351-9.
  • van der Tuin K, Tops CMJ, Adank MA et al. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2017;102(12):4534–40. doi: 10.1210/jc.2017-01249.
  • Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88(12):2887. doi: 10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>;2-f.
  • Iacobone M, Barzon L, Porzionato A et al. The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. Vol. 145, Surgery. 2009. p. 250. doi: 10.1016/j.surg.2008.06.027.
  • Iacobone M, Masi G, Barzon L et al. Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbeck’s Arch Surg. 2009;394(5):817–25. doi: 10.1007/s00423-009-0511-y.
  • Schulte KM, Talat N, Galata G et al. Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. Ann Surg Oncol. 2014;21(6):1891–7. doi: 10.1245/s10434-014-3530-z.
  • Villar-del-Moral J, Jimenez-Garcia A, Salvador-Egea P et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156(5):1132–44. doi: 10.1016/j.surg.2014.05.014.
  • Hsu K-T, Sippel RS, Chen H, Schneider DF. Is central lymph node dissection necessary for parathyroid carcinoma? Surgery. 2014;156(6):1336–41. doi: 10.1016/j.surg.2014.08.005.
  • Guan B, Welch JM, Sapp JC et al. GCM2-Activating Mutations in Familial Isolated Hyperparathyroidism. Am J Hum Genet. 2016;99(5):1034–44. doi: 10.1016/j.ajhg.2016.08.018.
  • Cardoso L, Stevenson M, Thakker R V. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat. 2017;38(12):1621–48. doi: 10.1002/humu.23337.
  • Kelly TG, Shattuck TM, Reyes-Mugica M et al. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res. 2006;21(10):1666–71. doi: 10.1359/jbmr.060702.
  • Hannan FM, Babinsky VN, Thakker R V. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016;57(3):R127-42. doi: 10.1530/JME-16-0124.



Abstract - 136

PDF (Russian) - 0



Copyright (c) Gorbacheva A., Eremkina A., Mokrysheva N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies